The Great Substitution: Why Investors Are Skipping Bonds For Dividend Stocks

Group 1 - The author has a background in biotechnology and has worked for major pharmaceutical companies and biotech startups, indicating a strong understanding of the sector [1] - The author is focused on managing wealth across different accounts with distinct goals, particularly in the biotech growth sector [1] - The author has co-founded a biotech company, 1200 Pharma, which has garnered significant investment, showcasing experience in attracting capital in the biotech industry [1] Group 2 - The author holds long positions in DGRO and IDV, indicating a bullish outlook on these investments [2][3] - The author may consider buying shares in SCHD or RSP depending on market conditions, suggesting a flexible investment strategy [3] - The author is also long ORCL in a growth portfolio, reflecting a diversified investment approach [3]